Mar 17, 2020   SOURCE: PR NewsWire

The PD-1 and PD-L1 Inhibitors Industry, 2020-2030 - Provides Detailed Analysis of 19+ Products along with 15+ Companies Involved

DUBLIN, March 17, 2020 /PRNewswire/ -- The "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The future of the competitive landscape of PD-1 and PD-L1 Inhibitors is estimated to be very strong. Key emerging drugs including Biocad's BCD-100 and others are going to be Blockbuster in the upcoming years.

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020 provides comprehensive insights on the therapeutic development for this mechanism of action.

The objective of the report is to establish an understanding of the therapeutic competitive landscape for PD-1 and PD-L1 Inhibitors, including the marketed and pipeline products in this space. The report provides detailed information on marketed products with historical and forecasted sales till 2030. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, licensing, deals, and other development activities is also involved in this report.

Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the understanding of the unmet needs, market drivers and barriers of the PD-1 and PD-L1 Inhibitors market.

This report on PD-1 and PD-L1 Inhibitors help companies in understanding market dynamics based on this mechanism of action and therefore giving opportunities for a strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition s will assuage companies to detect conditions, determine genetic predisposition and biological response to PD-1 and PD-L1 Inhibitors.

Scope of the Report

    --  The PD-1 and PD-L1 Inhibitors report provides an overview of this
        mechanism of action, role, significance, pathway, types, and clinical
        application of IDH inhibitors.
    --  Therapeutic Assessment: Therapeutic pipeline activity and assessment of
        the products by development stage, product type, route of
        administration, molecule type, and MOA the complete product development
        cycle, including all clinical and nonclinical stages.
    --  It comprises of detailed profiles of therapeutic products for PD-1 and
        PD-L1 Inhibitors with key coverage of developmental activities,
        including collaborations, agreements, licensing, mergers and
        acquisition, funding, designations, technology and other product-related
        details.
    --  In-depth PD-1 and PD-L1 Inhibitors research and development progress and
        trial details results wherever available, are also included in the
        pipeline study.
    --  Coverage of dormant and discontinued pipeline projects along with the
        reasons if available across PD-1 and PD-L1 Inhibitors.
    --  The report has also covered the worldwide market of PD-1 and PD-L1
        Inhibitors, information of marketed therapies, their historical and
        forecasted sales till 2030.
    --  It also includes patent expiry details impact on market after expiry.
    --  Key topics covered include strategic competitor assessment, market
        characterization, opportunities, unmet needs, market growth factors,
        barriers and challenges along with SWOT analysis of the PD-1 and PD-L1
        Inhibitors market.
    --  Analysis of the current and future market competition in the global PD-1
        and PD-L1 Inhibitors market. Current scenario of the market with
        upcoming blockbuster molecules and their impact on the overall market.

Report Highlights

    --  In the coming years, the PD-1 and PD-L1 Inhibitors market is set to
        change due to the extensive research in this filed, and incremental
        healthcare spending across the world; which would expand the size of the
        market to enable the drug manufacturers to penetrate more into the
        market.
    --  The companies and academics are working to assess challenges and seek
        opportunities that could influence PD-1 and PD-L1 Inhibitors R&D. The
        PD-1 and PD-L1 Inhibitors therapies under development are focused on
        novel approaches to treat/improve the disease condition.
    --  There are many companies involved in developing therapies for PD-1 and
        PD-L1 Inhibitors. Launch of emerging therapies of PD-1 and PD-L1
        Inhibitors will significantly impact the market.
    --  A better understanding of the target mechanism will also contribute to
        the development of novel therapeutics for PD-1 and PD-L1 Inhibitors.
    --  Our in-depth analysis of the pipeline assets (in early-stage, mid-stage
        and late-stage of development for the treatment of PD-1 and PD-L1
        Inhibitors includes therapeutic assessment and comparative analysis.
        This will support the clients in the decision-making process regarding
        their therapeutic portfolio by identifying the overall scenario of the
        research and development activities.
    --  The report provides the detailed analysis of 19+ products along with 15+
        companies involved.

Key Questions Answered

    --  What are PD-1 and PD-L1 Inhibitors, their role and significance in the
        treatment of disease conditions?
    --  What are the current treatment options based on the PD-1 and PD-L1
        Inhibitors available in the market?
    --  How the historical and forecasted sales of the marketed therapies
        determine their scenario in the current PD-1 and PD-L1 Inhibitors
        market?
    --  How many therapies are developed by each company for PD-1 and PD-L1
        Inhibitors to treat disease conditions?
    --  What are the key collaborations (Industry-Industry, Industry-Academia),
        mergers and acquisitions, licensing activities related to the PD-1 and
        PD-L1 Inhibitors therapies?
    --  Which are the dormant and discontinued products and the reasons for
        dormancy and discontinuation?
    --  What is the unmet need for current therapies developed on the basis of
        this mechanism of action?
    --  What are the recent novel therapies, targets, mechanisms of action and
        technologies developed to overcome the limitation of existing therapies?
    --  What are the clinical studies going on for PD-1 and PD-L1 Inhibitors and
        their status?

Companies Mentioned

    --  Keytruda
    --  Ono Pharmaceutical
    --  Genentech
    --  BeiGene
    --  Biocad
    --  Innovent Biologics
    --  and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fgwrie

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-pd-1-and-pd-l1-inhibitors-industry-2020-2030---provides-detailed-analysis-of-19-products-along-with-15-companies-involved-301025527.html

SOURCE Research and Markets